Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

560
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
560
Tumor Immunotherapy01:27

Tumor Immunotherapy

726
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
726

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to: Bhatia RK, Grieb SM, Anakwenze C, Rendle KA, Ngwa W, Grover S. Investigating the Uptake of Hypofractionation for Breast and Prostate Cancer in Sub-Saharan Africa: A Qualitative Study of Physician and Medical Physicist Perspectives. <i>Adv Radiat Oncol</i>. 2024;10:101683.

Advances in radiation oncology·2026
Same author

Radiation therapy in breast cancer patients in south west Nigeria: an evaluation of protocols in a specialist cancer centre.

BMC cancer·2026
Same author

Synergistic Effect of Linebacker-1 With Radiation Therapy in a Mouse Lung Cancer Model.

Advances in radiation oncology·2026
Same author

Cancer workforce-a global crisis: a Lancet Oncology Commission.

The Lancet. Oncology·2026
Same author

Artificial Intelligence in Radiation Treatment Planning: A Survey-Based Observational Study From A Cancer Centre in Nigeria.

Technology in cancer research & treatment·2026
Same author

Deployment of a Tailored and Hybrid Educational Strategy for Wartime Capacity Building: American Association of Physicists in Medicine/Help Ukraine Group/Ukrainian Association of Medical Physicists Training Program to Transition Ukraine From Co-60 to Intensity-Modulated Radiation Therapy.

JCO global oncology·2026

Related Experiment Video

Updated: Oct 13, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.3K

Optimizing In Situ Vaccination During Radiotherapy.

Sayeda Yasmin-Karim1,2,3, Jana Wood1,2,3,4, Johanna Wirtz1,2,3,5

  • 1Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA, United States.

Frontiers in Oncology
|November 12, 2021
PubMed
Summary

Smart biomaterials enhance in situ cancer vaccines by delivering anti-CD40, activating immune cells and improving treatment efficacy, especially in difficult-to-treat tumors.

Keywords:
abscopal effectcancer vaccinedose-paintingimmunogenic biomaterialsimmunotherapypancreatic cancerprostate cancerradiotherapy

More Related Videos

Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.4K
Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
05:18

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

1.6K

Related Experiment Videos

Last Updated: Oct 13, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.3K
Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.4K
Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
05:18

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

1.6K

Area of Science:

  • Immunology
  • Oncology
  • Biomaterials Science

Background:

  • Effective in situ cancer vaccines need tumor cell death and adjuvant to activate dendritic cells.
  • Radiotherapy (RT) and anti-CD40 show promise for in situ vaccination in preclinical models.

Purpose of the Study:

  • To investigate strategies for enhancing in situ vaccination using immunogenic biomaterials (IBM) loaded with anti-CD40.
  • To evaluate the efficacy of IBM-delivered anti-CD40 in cold tumors and the impact of checkpoint inhibitors.

Main Methods:

  • Utilized smart IBM loaded with anti-CD40 for delivery in pancreatic and prostate tumor models.
  • Assessed immune cell infiltration (dendritic cells, CD8+ T cells) and tumor response.
  • Examined the combination of IBM-based in situ vaccination with downstream immune checkpoint inhibitors.

Main Results:

  • IBM delivery of anti-CD40 significantly enhanced in situ vaccination efficacy in pancreatic and prostate cancers compared to direct injection.
  • Observed increased antigen-presenting cell and CD8+ cytotoxic T lymphocyte infiltration in tumors.
  • IBM-mediated in situ vaccination demonstrated consistent efficacy across different tumor types.
  • Combination with checkpoint inhibitors further improved overall survival.

Conclusions:

  • Immunogenic biomaterials offer a potent strategy for enhancing anti-CD40-based in situ vaccination, particularly in immunologically cold tumors.
  • This approach promotes systemic anti-tumor immunity and improves survival outcomes.
  • Findings support the development of IBM for combination cancer therapy with radiotherapy.